Skip to main content
Erschienen in: Pathology & Oncology Research 2/2014

01.04.2014 | Research

Fas Gene Variants in Childhood Acute Lymphoblastic Leukemia and Association with Prognosis

verfasst von: Behnaz Valibeigi, Zahra Amirghofran, Hossein Golmoghaddam, Reza Hajihosseini, Fatemeh M. Kamazani

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Fas molecule is one of the main important molecules involved in apoptotic cell death. Single nucleotide polymorphisms in the promoter of Fas gene at positions −1377G/A and −670 A/G may affect its expression and play an important role in the pathology of leukemia. In the present study the association between these polymorphisms and risk of the development of acute lymphoblastic leukemia (ALL) in children with ALL compared to cancer-free control subjects was examined by polymerase chain reaction- based restriction fragment length polymorphism. The relationship between the polymorphisms and clinical and laboratory features of the patients and response to therapy were determined. No significant differences in genotype and allele frequencies between the patients and the control subjects at positions −670 and −1377 were detected. Evaluation of the prognostic factors revealed an association between the GG genotype at position −670 and liver involvement in ALL patients (p < 0.04). Although patients with −1377 AA genotype showed shorter mean complete remission duration, the result of survival analysis did not reach to be significant. In conclusion, results of this study showed no contribution of Fas genotypes at positions −670 and −1377 to risk of ALL in children. The association of Fas GG genotype at position −670 with liver involvement in the patients may show its important role in prognosis of ALL.
Literatur
1.
Zurück zum Zitat Daneshbod Y, Amirghofran Z, Tabei SZ (2005) Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients. Neoplasma 52:109–114PubMed Daneshbod Y, Amirghofran Z, Tabei SZ (2005) Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients. Neoplasma 52:109–114PubMed
2.
Zurück zum Zitat Amirghofran Z, Monabati A, Gholijani N (2004) Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer. Pathol Oncol Res 10:37–41PubMedCrossRef Amirghofran Z, Monabati A, Gholijani N (2004) Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer. Pathol Oncol Res 10:37–41PubMedCrossRef
5.
Zurück zum Zitat Itoh N, Yonehara S (2000) The polypeptide encoded by the cDNA for human cell surface antigen FAS can mediate apoptosis. Cell 66:233–243CrossRef Itoh N, Yonehara S (2000) The polypeptide encoded by the cDNA for human cell surface antigen FAS can mediate apoptosis. Cell 66:233–243CrossRef
6.
Zurück zum Zitat Inazawa J, Itoh N, Abe T, Nagata S (1992) Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 14:821–822PubMedCrossRef Inazawa J, Itoh N, Abe T, Nagata S (1992) Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 14:821–822PubMedCrossRef
7.
Zurück zum Zitat Behrmann I, Walczak H, Krammer PH (1994) Structure of the human APO-1 gene. Eur J Immunol 24:3057–3062PubMedCrossRef Behrmann I, Walczak H, Krammer PH (1994) Structure of the human APO-1 gene. Eur J Immunol 24:3057–3062PubMedCrossRef
8.
Zurück zum Zitat Muschen M, Warskulat U, Beckmann MW (2000) Defining CD95 as a tumor suppressor gene. J Mol Med 78:312–325PubMedCrossRef Muschen M, Warskulat U, Beckmann MW (2000) Defining CD95 as a tumor suppressor gene. J Mol Med 78:312–325PubMedCrossRef
9.
Zurück zum Zitat Sibley K, Rollinson S, Allan JM et al (2003) Functional Fas promoter polymorphism are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330PubMed Sibley K, Rollinson S, Allan JM et al (2003) Functional Fas promoter polymorphism are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330PubMed
10.
Zurück zum Zitat Wu J, Siddiqui J, Nihal M, Vonderheid EC et al (2011) Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys 15:185–191CrossRef Wu J, Siddiqui J, Nihal M, Vonderheid EC et al (2011) Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys 15:185–191CrossRef
11.
Zurück zum Zitat Zhang Z, Xue H, Gong W et al (2009) FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 30:487–493PubMedCrossRef Zhang Z, Xue H, Gong W et al (2009) FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 30:487–493PubMedCrossRef
12.
Zurück zum Zitat Lei D, Sturgis EM, Wang LE et al (2010) FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 19:1484–1491PubMedCentralPubMedCrossRef Lei D, Sturgis EM, Wang LE et al (2010) FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 19:1484–1491PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Cao Y, Miao XP, Huang MY et al (2010) Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog 49:944–950PubMedCrossRef Cao Y, Miao XP, Huang MY et al (2010) Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog 49:944–950PubMedCrossRef
14.
Zurück zum Zitat Shao P, Ding Q, Qin C et al (2011) Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population. Prostate 71:1122–1130PubMedCrossRef Shao P, Ding Q, Qin C et al (2011) Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population. Prostate 71:1122–1130PubMedCrossRef
15.
Zurück zum Zitat Zhang W, Li C, Wang J, He C (2012) Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma. Hepatogastroenterology 59:141–146PubMedCrossRef Zhang W, Li C, Wang J, He C (2012) Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma. Hepatogastroenterology 59:141–146PubMedCrossRef
16.
Zurück zum Zitat Zhang X, Miao X, Sun T et al (2005) Functional polymorphisms in cell death pathway genes Fas and FasL contribute to risk of lung cancer. J Med Genet 42:479–484PubMedCentralPubMedCrossRef Zhang X, Miao X, Sun T et al (2005) Functional polymorphisms in cell death pathway genes Fas and FasL contribute to risk of lung cancer. J Med Genet 42:479–484PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Scholl V, Stefanoff CG, Hassan R et al (2007) Spector N, Renault IZ. Mutations within the 5′ region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma. Leuk Lymphoma 48:957–963PubMedCrossRef Scholl V, Stefanoff CG, Hassan R et al (2007) Spector N, Renault IZ. Mutations within the 5′ region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma. Leuk Lymphoma 48:957–963PubMedCrossRef
18.
Zurück zum Zitat Peter AM, Kohfink B, Martin H et al (1999) Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin’s disease. Exp Hematol 27:868–874CrossRef Peter AM, Kohfink B, Martin H et al (1999) Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin’s disease. Exp Hematol 27:868–874CrossRef
19.
Zurück zum Zitat Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS (1997) Mutations in the Fas antigen in patients with multiple myeloma. Blood 90:4266–4270PubMed Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS (1997) Mutations in the Fas antigen in patients with multiple myeloma. Blood 90:4266–4270PubMed
20.
Zurück zum Zitat Farre L, Bittencourt AL, Silva-Santos G et al (2008) Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol 83:220–222PubMedCrossRef Farre L, Bittencourt AL, Silva-Santos G et al (2008) Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol 83:220–222PubMedCrossRef
21.
Zurück zum Zitat Nair RR, Khanna A, Singh K (2012) Association of FAS −1377 G > A and FAS −670 A > G functional polymorphisms of FAS gene of cell death pathway with recurrent early pregnancy loss risk. J Reprod Immunol 93:114–118PubMedCrossRef Nair RR, Khanna A, Singh K (2012) Association of FAS −1377 G > A and FAS −670 A > G functional polymorphisms of FAS gene of cell death pathway with recurrent early pregnancy loss risk. J Reprod Immunol 93:114–118PubMedCrossRef
22.
Zurück zum Zitat Zhao XF, Reitz M, Chen QC, Stass S (2011) Pathogenesis of early leukemia and lymphoma. Cancer Biomark 9:341–374 Zhao XF, Reitz M, Chen QC, Stass S (2011) Pathogenesis of early leukemia and lymphoma. Cancer Biomark 9:341–374
23.
Zurück zum Zitat Traver D, Akashi K, Weissman IL, Lagasse E (1998) Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9:47–57PubMedCrossRef Traver D, Akashi K, Weissman IL, Lagasse E (1998) Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9:47–57PubMedCrossRef
24.
Zurück zum Zitat Chávez-Galán L, Arenas-Del Angel MC, Zenteno E et al (2009) Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 6:15–25PubMedCrossRef Chávez-Galán L, Arenas-Del Angel MC, Zenteno E et al (2009) Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 6:15–25PubMedCrossRef
25.
Zurück zum Zitat Arasteh JM, Sarvestani EK, Aflaki E, Amirghofran Z (2010) Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules. Immunol Investig 39:27–38CrossRef Arasteh JM, Sarvestani EK, Aflaki E, Amirghofran Z (2010) Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules. Immunol Investig 39:27–38CrossRef
26.
Zurück zum Zitat Villa-Morales M, Fernández-Piqueras J (2012) Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets 16:85–101PubMedCrossRef Villa-Morales M, Fernández-Piqueras J (2012) Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets 16:85–101PubMedCrossRef
27.
Zurück zum Zitat Rozenfeld-Granot G, Toren A, Amariglio N (2001) Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies. Exp Hematol 29:228–233PubMedCrossRef Rozenfeld-Granot G, Toren A, Amariglio N (2001) Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies. Exp Hematol 29:228–233PubMedCrossRef
28.
Zurück zum Zitat Beltinger C, Kurz E, Böhler T (1998) CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 15:3943–3951 Beltinger C, Kurz E, Böhler T (1998) CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 15:3943–3951
29.
Zurück zum Zitat Beltinger C, Böhler T, Karawajew L et al (1998) Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia. Br J Haematol 102:722–728PubMedCrossRef Beltinger C, Böhler T, Karawajew L et al (1998) Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia. Br J Haematol 102:722–728PubMedCrossRef
30.
Zurück zum Zitat Kim HJ, Jin XM, Kim HN et al (2010) Fas and FasL polymorphisms are not associated with acute myeloid leukemia risk in Koreans. DNA Cell Biol 29:619PubMedCrossRef Kim HJ, Jin XM, Kim HN et al (2010) Fas and FasL polymorphisms are not associated with acute myeloid leukemia risk in Koreans. DNA Cell Biol 29:619PubMedCrossRef
31.
Zurück zum Zitat Mehta PA, Gerbing RB, Alonzo TA et al (2008) FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children’s oncology group report. Clin Cancer Res 1:7896–7899CrossRef Mehta PA, Gerbing RB, Alonzo TA et al (2008) FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children’s oncology group report. Clin Cancer Res 1:7896–7899CrossRef
32.
Zurück zum Zitat Amirghofran Z, Daneshbod Y, Gholijani N, Esmaeilbeig M (2011) The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acute lymphoblastic leukemia. Arch Iran Med 14:170–174PubMed Amirghofran Z, Daneshbod Y, Gholijani N, Esmaeilbeig M (2011) The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acute lymphoblastic leukemia. Arch Iran Med 14:170–174PubMed
33.
Zurück zum Zitat Amirghofran Z, Daneshbod Y, Gholijani N (2009) Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome. Oncol Res 17:447–454PubMedCrossRef Amirghofran Z, Daneshbod Y, Gholijani N (2009) Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome. Oncol Res 17:447–454PubMedCrossRef
34.
Zurück zum Zitat Fathi M, Amirghofran Z, Shahriari M (2012) Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Med Oncol 29:2046–2052PubMedCrossRef Fathi M, Amirghofran Z, Shahriari M (2012) Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Med Oncol 29:2046–2052PubMedCrossRef
35.
Zurück zum Zitat Sunter NJ, Scott K, Hills R et al (2012) A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 5:196–205CrossRef Sunter NJ, Scott K, Hills R et al (2012) A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 5:196–205CrossRef
Metadaten
Titel
Fas Gene Variants in Childhood Acute Lymphoblastic Leukemia and Association with Prognosis
verfasst von
Behnaz Valibeigi
Zahra Amirghofran
Hossein Golmoghaddam
Reza Hajihosseini
Fatemeh M. Kamazani
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2014
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-013-9705-2

Weitere Artikel der Ausgabe 2/2014

Pathology & Oncology Research 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.